```html

Bleeding Peptic Ulcer – A Comprehensive Medical Guide

Overview

A peptic ulcer is a sore that develops on the lining of the stomach (gastric ulcer), the first part of the small intestine called the duodenum (duodenal ulcer), or, less commonly, the lower esophagus. When the ulcer erodes a blood vessel, it can cause bleeding, ranging from occult (hidden) loss to massive hemorrhage that requires urgent care.

• Who it affects: Adults of any age, but most cases occur in people aged 40‑70 years.
• Gender: Slight male predominance (approximately 55 % men, 45 % women) in most Western populations.
• Prevalence: Peptic ulcer disease (PUD) affects about 5–10 % of the global population. Bleeding occurs in roughly 10–20 % of ulcer patients, making it a leading cause of hospitalization for gastrointestinal (GI) bleeding.

Symptoms

Bleeding ulcers can present with a wide spectrum of signs, depending on the amount and rate of blood loss.

• Upper‑GI bleeding (hematemesis): Vomiting of fresh red blood or “coffee‑ground” material (digested blood).
• Melena: Black, tarry stools indicating digested blood; often a sign of slower bleeding.
• Hematemesis + melena together: Suggests ongoing or recurrent bleeding.
• Occult blood loss: No visible blood, but a positive fecal occult blood test; may cause iron‑deficiency anemia.
• Symptoms of anemia: Fatigue, weakness, shortness of breath, palpitations, or dizziness.
• Abdominal pain: Burning or gnawing pain centered in the upper abdomen, often relieved by food (duodenal) or worsened by food (gastric).
• Signs of shock (rare, but emergency): Rapid heartbeat, low blood pressure, cold clammy skin, confusion.
• Other nonspecific signs: Nausea, loss of appetite, weight loss.

Causes and Risk Factors

The underlying ulcer usually forms because the protective mucosal barrier is compromised. Bleeding happens when an ulcer erodes a submucosal blood vessel.

Primary Causes

1. Helicobacter pylori infection: This bacterium weakens the mucosal lining and is responsible for up to 70 % of duodenal and 30 % of gastric ulcers.<sup>CDC</sup>
2. Non‑steroidal anti‑inflammatory drugs (NSAIDs): Aspirin, ibuprofen, naproxen, and selective COX‑2 inhibitors impair prostaglandin synthesis, reducing mucus production.<sup>NHS</sup>
3. Other medications: Steroids, anticoagulants (warfarin, DOACs), and antiplatelet agents (clopidogrel) increase bleeding risk.
4. Stress‑related mucosal damage: Severe illness, trauma, or burns (Curling’s ulcer) can precipitate bleeding.

Risk Factors

• Age > 60 years (reduced mucosal repair capacity).
• Heavy alcohol consumption (irritates mucosa, raises gastric acid).
• Smoking (impairs healing, increases acid secretion).
• Chronic liver disease or cirrhosis (portal hypertension → variceal‑like bleeding).
• History of prior ulcer or previous GI bleeding.
• High‑dose or prolonged use of NSAIDs or aspirin.
• Genetic predisposition (certain CYP2C19 polymorphisms affect drug metabolism).

Diagnosis

Prompt evaluation is essential because bleeding can be life‑threatening.

Initial Assessment

• History & physical exam: Assess timing, amount of blood, associated pain, medication use, and risk factors.
• Vital signs: Look for tachycardia, hypotension, orthostatic changes.
• Laboratory tests:
  • Complete blood count (CBC) – hemoglobin/hematocrit trends.
  • Basic metabolic panel – assess electrolytes, BUN/creatinine (high BUN:Cr ratio may suggest upper GI bleed).
  • Coagulation profile (PT/INR, aPTT) if on anticoagulants.
  • Fecal occult blood test if melena is not evident.

Imaging & Endoscopic Evaluation

1. Upper endoscopy (esophagogastroduodenoscopy, EGD): Gold‑standard; performed within 24 hours for most patients and within 12 hours for unstable patients. Allows direct visualization, grading of bleeding (Forrest classification), and therapeutic interventions (e.g., clipping, injection).
2. Contrast‑enhanced CT angiography: Used when endoscopy is not immediately feasible or to localize active arterial bleeding.
3. Radionuclide (99mTc) scan: Detects low‑rate bleeding (<0.5 mL/min) but less specific.

Testing for Underlying Causes

• Urea breath test, stool antigen test, or gastric biopsy for H. pylori.
• Serology for autoimmune gastritis if clinically indicated.

Treatment Options

Treatment combines stabilization, eradication of the cause, and definitive ulcer therapy.

1. Acute Stabilization

• Fluid resuscitation: Crystalloid (e.g., normal saline) titrated to maintain MAP ≥ 65 mmHg.
• Blood transfusion: Target hemoglobin > 7 g/dL in most patients; higher thresholds (≥ 8–9 g/dL) for cardiovascular disease.
• Proton pump inhibitor (PPI) infusion: High‑dose IV PPI (e.g., omeprazole 80 mg bolus then 8 mg/h) reduces rebleeding risk (Cochrane review 2020).<sup>Cochrane</sup>
• Correction of coagulopathy: Vitamin K, fresh frozen plasma, or prothrombin complex concentrate as indicated.

2. Endoscopic Therapy (performed during EGD)

• Thermal coagulation: Heater probe or bipolar electrocoagulation.
• Injection: Epinephrine (1:10,000) to cause vasoconstriction.
• Mechanical: Hemoclips or over‑the‑scope clips to close the vessel.
• Topical hemostatic powders: E.g., Hemospray, useful for diffuse oozing.

Combination therapy (injection + thermal/mechanical) is recommended for visible vessels (Forrest Ia/Ib).

3. Pharmacologic Management

Medication	Indication	Typical Dose
Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole)	Ulcer healing, reduce acid‐mediated rebleeding	IV 80 mg bolus then 8 mg/h; transition to oral 20–40 mg daily for 4–8 weeks
H. pylori eradication regimen	Positive H. pylori test	Triple therapy: PPI + clarithromycin 500 mg bid + amoxicillin 1 g bid for 14 days (or bismuth quadruple if resistance suspected)
Discontinue NSAIDs/aspirin	Medication‑related ulcer	Switch to acetaminophen for analgesia; if aspirin needed for cardioprotection, consider low‑dose and co‑prescribe PPI
Octreotide (somatostatin analog)	Severe portal hypertension‑related bleeding (rare)	IV 50 µg bolus then 50 µg/h

4. Surgical / Radiologic Interventions

• Angiographic embolization: For patients who fail endoscopic control or are poor surgical candidates.
• Surgery: Partial gastrectomy or oversewing of the bleeding ulcer; reserved for refractory or massive hemorrhage.

5. Long‑Term Maintenance

• Continue a standard dose PPI for 8–12 weeks (or longer if high risk).
• Confirm H. pylori eradication with a urea breath test ≥ 4 weeks after therapy.
• Avoid NSAIDs; use COX‑2 selective agents with a PPI if analgesia is required.

Living with Bleeding Peptic Ulcer

Even after successful treatment, lifestyle habits influence recurrence and overall health.

Daily Management Tips

• Medication adherence: Take PPIs exactly as prescribed; set reminders.
• Dietary adjustments:
  • Avoid spicy, acidic, and fatty foods that can irritate the ulcer.
  • Eat smaller, more frequent meals rather than large meals.
  • Limit caffeine and carbonated beverages.
• Alcohol & smoking: Stop smoking and limit alcohol (≤ 1 drink/day for women, ≤ 2 for men).
• Stress management: Incorporate relaxation techniques—mindfulness, yoga, or short walks.
• Regular follow‑up: Endoscopy 6–8 weeks after healing if high‑risk features existed.
• Monitor for anemia: Periodic CBC checks, especially if you notice fatigue or pale skin.

Prevention

Many risk factors are modifiable.

• Test and treat H. pylori: Screening is recommended for patients with a history of ulcer disease, especially in high‑prevalence regions.
• Use NSAIDs cautiously: Take with food, limit to lowest effective dose, and always pair with a PPI if prolonged use is unavoidable.
• Vaccination: While no vaccine exists for H. pylori, routine vaccinations (e.g., hepatitis B) reduce liver disease that can aggravate bleeding risk.
• Maintain a healthy weight: Obesity is associated with increased gastric acid secretion.
• Regular medical review: Patients on chronic anticoagulation should have INR or DOAC levels checked regularly.

Complications

If bleeding is not controlled, serious sequelae may develop.

• Severe anemia: May cause cardiac ischemia, especially in older adults.
• Perforation: Full‑thickness ulcer breach leading to peritonitis; requires emergent surgery.
• Penetration: Ulcer extends into adjacent organs (e.g., pancreas, liver) causing localized pain.
• Gastric outlet obstruction: Chronic inflammation leads to scarring and narrowing.
• Re‑bleeding: Occurs in 10–20 % of patients within 30 days, emphasizing the need for follow‑up care.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Peptic ulcer disease. https://www.mayoclinic.org/diseases-conditions/peptic-ulcer/symptoms-causes/syc-20354223 (accessed May 2026).
2. CDC. Helicobacter pylori (H. pylori) infection. https://www.cdc.gov/helicobacter/ (accessed May 2026).
3. NIH National Institute of Diabetes and Digestive and Kidney Diseases. Peptic ulcer. https://www.niddk.nih.gov/health-information/digestive-diseases/peptic-ulcer (accessed May 2026).
4. Cochrane Library. Proton pump inhibitors for ulcer bleeding. 2020 review. https://www.cochranelibrary.com (accessed May 2026).
5. Cleveland Clinic. Upper gastrointestinal bleeding. https://my.clevelandclinic.org/health/diseases/16540-upper-gastrointestinal-bleeding (accessed May 2026).
6. World Health Organization. Guidelines for the management of peptic ulcer disease. 2023. https://www.who.int (accessed May 2026).

```